TP53 and glioblastoma: To evaluate this further, it would be necessary to correlate the CSF metabolite findings with MRS imaging and perform receiver-operator curve analysis to detect the sensitivity and specificity of a given cut-off on MRS that reliably predicts TP53 and PTEN mutation status when GBM tissue is not available.